Cisplatin in cancer therapy: Molecular mechanisms of action
Top Cited Papers
- 1 October 2014
- journal article
- review article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 740, 364-378
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 182 references indexed in Scilit:
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and managementMolecular Oncology, 2009
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Protein kinase Cε makes the life and death decisionCellular Signalling, 2007
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- A new p38 MAP kinase‐regulated transcriptional coactivator that stimulates p53‐dependent apoptosisThe EMBO Journal, 2007
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002